NCT02835586View on ClinicalTrials.gov

STREAMER : STent Restenosis And MEdicaments Release

PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Critical Ischemia
Interventions
DRUG

Paclitaxel

Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3

Trial Locations (1)

69003

department of vascular surgery, Edouard Herriot Hospital, 5 Place d'Arsonval, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02835586 - STREAMER : STent Restenosis And MEdicaments Release | Biotech Hunter | Biotech Hunter